Rocket Pharmaceuticals, Inc. RCKT
2.60
(0.09)
(3.35%)
as of 25 Sep
- Market cap
- $300.8M
- P/E
- 0.0×
Follow RCKT
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
9.24 | 6.12 | 6.38 | 7.30 |
+8 more quarters Free account |
Net Debt/EBITDA |
5.90 | 2.70 | 4.09 | 4.15 | |
Debt/Assets |
4.57% | 6.78% | 5.86% | 5.26% | |
Debt/Equity |
0.05 | 0.08 | 0.07 | 0.06 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(0.32) | 0.95 | 0.82 | 1.00 | |
Capex/Depreciation |
0.00 | (0.04) | (0.03) | 0.02 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.15 | 0.23 | 0.19 | 0.17 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.35) | (0.41) | (0.31) | (0.45) | |
Cash per Share |
2.51 | 1.29 | 1.70 | 2.00 | |
Shareholders Equity per Share |
3.27 | 2.12 | 2.49 | 2.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.27 | 2.12 | 2.49 | 2.81 | |
Free Cash Flow |
(39.62) | (45.49) | (34.92) | (50.37) | |
Working Capital |
258.23 | 125.36 | 162.53 | 196.51 | |
Capital Expenditures |
(0.01) | (0.09) | (0.08) | 0.05 | |
Net Current Asset Value |
235.28 | 102.46 | 139.51 | 173.32 | |
| Other line items | |||||
Quick Ratio |
9.06 | 5.90 | 6.25 | 7.15 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.35) | (0.40) | (0.31) | (0.45) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
34.42 | 26.99 | 32.56 | 32.70 | |
Average Assets |
422.04 | 378.24 | 429.07 | 380.86 | |
Average Common Equity |
361.52 | 325.09 | 370.23 | 321.72 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates